What's in Jakob Møller Hansen, MD.'s pipeline?

Jakob Møller Hansen, MD. has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Jakob Møller Hansen, MD.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/jakob-m-ller-hansen-md.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Jakob Møller Hansen, MD. — Portfolio Competitive Intelligence Brief

Jakob Møller Hansen, MD. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Betamethasone and local anesthetic	Betamethasone and local anesthetic	marketed	Corticosteroid with local anesthetic	Glucocorticoid receptor (betamethasone); voltage-gated sodium channels (local anesthetic component)	Dermatology, Rheumatology, Pain Management

Therapeutic area mix

Dermatology, Rheumatology, Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Jakob Møller Hansen, MD.:

Cite this brief

Drug Landscape (2026). Jakob Møller Hansen, MD. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jakob-m-ller-hansen-md. Accessed 2026-05-16.